Test two chemotherapy combos before breast surgery for triple-negative cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old
- Your breast cancer has been confirmed as triple-negative invasive breast cancer
- Your planned treatment includes chemotherapy before surgery, and your breast tumor is larger than 2 cm
- You have at least one measurable cancer spot based on standard scan rules
- Your heart pumping strength is good (left-ventricular ejection fraction at least 55%) and your energy level is low enough (ECOG 0–1)
- You have adequate blood, kidney, and liver test results, and you can give required blood and tumor tissue samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests which chemotherapy drug works better before surgery (neoadjuvant therapy) for triple-negative breast cancer that has spread to underarm lymph nodes. It compares two forms of paclitaxel given by random assignment to see which option may shrink the tumor more effectively and improve outcomes.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.